Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Characterizing alanine transporters as therapeutic targets for pancreatic cancer

FY 2021-22

Summary
Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest cancer survival rates, impacting thousands of Canadians annually. Despite modest improvements in the past 20 years, long-term survival rates are still only 10%. New therapy targets are urgently needed to improve patient outcomes and survival. It has been shown that PDAC cells have a significant demand for the amino acid alanine through unknown mitochondrial alanine transporter(s). Protein transporters are the gatekeepers of the cell that control metabolite import and export. Targeting cell surface alanine transporters attenuates alanine uptake and metabolism and leads to decreased PDAC tumour growth and, in some cases, complete regression. The SLC25 solute carrier family make up the majority of mitochondrial transport proteins. However, approximately 30% of SLCs remain uncharacterized to date. This proposal addresses this metabolic axis, in hopes of identifying and characterizing the unknown mitochondrial transporter(s) as potential targets for PDAC. A CRISPR/Cas9-mediated knock-out (KO) approach will be used to study transporters in depth and define the gene-phenotype relationships. Highly-sensitive molecular tools like mass-spectrometry will be employed to measure metabolite release in the mitochondria and confirm alanine transport activity. The transporter candidates will be characterized for their effects on PDAC and non-malignant cell proliferation and tumour growth using subcutaneous xenografts in mice. This work is significant for patients with PDAC to improve their prognosis by providing insight into new and effective therapeutics.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
466496
Name
Johal Danisha
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing alanine transporters as therapeutic targets for pancreatic cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Metabolism; Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; Solute Carriers; Therapeutics; Transporters; Treatment
Abstract
Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest cancer survival rates, impacting thousands of Canadians annually. Despite modest improvements in the past 20 years, long-term survival rates are still only 10%. New therapy targets are urgently needed to improve patient outcomes and survival. It has been shown that PDAC cells have a significant demand for the amino acid alanine through unknown mitochondrial alanine transporter(s). Protein transporters are the gatekeepers of the cell that control metabolite import and export. Targeting cell surface alanine transporters attenuates alanine uptake and metabolism and leads to decreased PDAC tumour growth and, in some cases, complete regression. The SLC25 solute carrier family make up the majority of mitochondrial transport proteins. However, approximately 30% of SLCs remain uncharacterized to date. This proposal addresses this metabolic axis, in hopes of identifying and characterizing the unknown mitochondrial transporter(s) as potential targets for PDAC. A CRISPR/Cas9-mediated knock-out (KO) approach will be used to study transporters in depth and define the gene-phenotype relationships. Highly-sensitive molecular tools like mass-spectrometry will be employed to measure metabolite release in the mitochondria and confirm alanine transport activity. The transporter candidates will be characterized for their effects on PDAC and non-malignant cell proliferation and tumour growth using subcutaneous xenografts in mice. This work is significant for patients with PDAC to improve their prognosis by providing insight into new and effective therapeutics.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Johal, Danisha
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~